KAUST and Saudi healthtech company amplifAI health have signed an MoU to develop a new disease detection system. The system will combine amplifAI's AI technology with KAUST's HyplexTM hyperspectral imaging, initially for diabetic foot complications. Clinical trials are planned, with aims to reduce amputations and save Saudi Arabia over 2 billion Riyals annually. Why it matters: This partnership showcases the potential of combining Saudi AI and advanced imaging technologies to address pressing healthcare challenges in the region, particularly diabetes.
MBZUAI researchers developed FetalCLIP, an AI model trained on 210,000 ultrasound images for fast and reliable interpretation of fetal scans. MBZUAI's President Eric Xing contributed to the General Expression Transformer (GET), an AI foundation model acting as a biological simulator to predict gene behavior. MBZUAI and Carleton University created MedPromptX for quicker disease diagnosis and treatment plans using multimodal AI. Why it matters: These AI advancements from MBZUAI have the potential to revolutionize healthcare in the region and globally, from prenatal care to drug discovery and personalized medicine.
MBZUAI researchers are developing AI applications for malaria prevention in Indonesia using sensory data fusion and digital twins. Another MBZUAI team is using machine learning and computer vision to detect cardiovascular disease from CT scans in collaboration with the University of Oxford. AI-powered remote patient monitoring is also being explored for proactive interventions and chronic disease management. Why it matters: These projects demonstrate the potential of AI to address healthcare challenges in underserved communities and improve disease prevention and management in the region.
MBZUAI is developing AI algorithms to intelligently process data from wearables and home sensors for remote patient monitoring. The algorithms aim to analyze multiple strands of health data to provide a more comprehensive view of a patient's health, distinguishing between genuine emergencies and benign situations. MBZUAI's provost, Professor Fakhri Karray, believes this approach could handle 20-25% of diagnoses virtually, reducing the burden on healthcare systems. Why it matters: This research could significantly improve healthcare efficiency and accessibility in the UAE and beyond by enabling more effective remote patient monitoring and reducing unnecessary hospital visits.
The AI4Bio Workshop at MBZUAI explored the intersection of AI and biology, focusing on AI-driven virtual organisms and foundation models. Eric Xing presented his vision of using AI to simulate biological activities, offering a safer alternative to physical experiments. Researchers like Le Song and Jen Philippe Vert are developing foundation models for biological systems, enhancing drug discovery and bioengineering. Why it matters: This signals the growing importance of AI in advancing biological research and healthcare innovation within the UAE and globally.
Pierre Baldi from UC Irvine presented applications of AI to biomedicine, covering molecular-level analysis of circadian rhythms, real-time polyp detection in colonoscopy videos, and prediction of post-operative adverse outcomes. He discussed integrating AI in future AI-driven hospitals. The presentation was likely part of a panel discussion hosted by MBZUAI in collaboration with the Manara Center for Coexistence and Dialogue. Why it matters: This highlights the growing interest in AI applications within the healthcare sector in the UAE, particularly through institutions like MBZUAI.
A report discusses using AI to optimize healthcare delivery across the entire medical process cycle, including pre-hospital screening, in-hospital treatment, and post-hospital rehabilitation. It considers optimal management of workflow, medical resources, and comprehensive healthcare coverage. Dr. Jingshan Li from Tsinghua University is the author, with extensive publications and experience in production and healthcare systems. Why it matters: AI-driven improvements to healthcare processes could lead to better resource allocation and enhanced patient outcomes across the GCC region.
MBZUAI hosted a two-day workshop on "Big Model AI in Drug Design" starting February 20, 2023. The workshop featured presentations from researchers in public and private institutions working on AI and health. MBZUAI Adjunct Professor Eran Segal opened the workshop with a talk on the Human Phenotype Project. Why it matters: The event highlights the growing interest and activity in applying AI, particularly large models, to advance drug discovery and personalized medicine within the UAE's research ecosystem.